United States RE41134 (Tretinoin) Patent Landscape: Scope of Claims, Claim Boundaries, and Competitive Implications
What is RE41134 and what does it claim?
RE41134 is a US reissue patent built around a stable, aqueous topical retinoid formulation that delivers tretinoin (and close equivalents) with slow release and reduced irritancy, supported by an explicit formulation architecture:
- Aqueous medium with at least 40 wt% water
- High molecular weight polyacrylic acid (PAA) gelling agent neutralized to pH 3 to 7 to form a gel and hold tretinoin for slow release
- Antioxidant to retard tretinoin decomposition in water
- Optional formulating elements: solubilizer (e.g., ethanol), non-ionic emulsifier (e.g., glycol), surfactants, lipophilic agent, preservative, chelating agent (EDTA salts)
The claims also include a matched method of treatment claim that turns the composition into a topical regimen.
This is a formulation and method-of-use fence: most design-around strategies must change either (1) the aqueous gel matrix (PAA + pH window), (2) the antioxidant-retention mechanism, (3) the composition class (non-aqueous, different gel former), or (4) the functional performance framing (“slow release” and “minimal irritancy”).
How broad is the core claim language (independent claim 1)?
Claim 1 is the center of gravity. It is structured as “a stable, aqueous retinoid composition” with four required elements (a) through (d).
Independent claim 1: required limitations that drive scope
| Limitation in claim 1 |
What it requires (as claimed) |
Practical boundary for competitors |
| (a) Aqueous medium |
Composition is at least about 40 wt% water |
Clear separation from anhydrous or predominantly non-aqueous systems; “water-based” is mandatory. |
| (b) Retinoid |
Retinoid is tretinoin |
Excludes other retinoids unless they fall into later dependent coverage or equivalents not captured in this reissue text. |
| (c) Gelling agent |
High molecular weight polyacrylic acid neutralized to pH about 3 to 7; forms gel and holds retinoid for slow release |
Tightest formulation determinant. If the gel former is not high MW PAA, or if pH is outside 3-7, the core claim is missed. |
| (d) Antioxidant |
Antioxidant effective to retard tretinoin decomposition in aqueous medium |
Must have an antioxidant meeting the claimed purpose. Lack of antioxidant (or antioxidant that does not function to retard decomposition) risks non-infringement. |
Functional words that matter in enforcement
The claim uses functional phrasing:
- “form a gel and hold said retinoid for slow release”
- “minimal irritancy to the skin”
- “retard decomposition”
In a litigation posture, these usually become points of evidentiary leverage for claim construction and infringement proof. Practically, they also guide how a generic or branded competitor will try to reframe formulation performance.
What does dependent claim coverage add (claims 2 through 15 for composition)?
Dependent claims narrow with explicit ranges and enumerated ingredient lists. They also give multiple “pick one” options, which expands coverage within each dependent claim.
Quantity ranges (claim 2)
Claim 2 locks in typical formulation windows:
- Retinoid (tretinoin): 0.01 to 0.1 wt%
- PAA gelling agent: 0.1 to 10 wt%
- Antioxidant: 0.01 to 4 wt%
- Water: at least 50 wt%
This is meaningful because it captures a large middle band of typical topical strengths, while leaving some “escape” for outside these ranges. Under US claim practice, claim 1 still covers outside the dependent ranges, but those are the ranges most likely to be tested and marketed.
Ingredient identification (claims 3 and 4)
- Claim 3: tretinoin plus “derivatives” and “derivations” language: “selected from the group consisting of tretinoin and effective, dermatologically acceptable salts, isomers and derivatives thereof.”
- Claim 4: antioxidant selection set:
- dl-alpha-tocopherol
- butylated hydroxyanisole (BHA)
- butylated hydroxytoluene (BHT)
- ascorbyl palmitate
- propyl gallate
This means antioxidant choice is not free-form; it is anchored to enumerated exemplars in the dependent claim. A competitor can still include other antioxidants under claim 1, but claim 4 specifically calls out those five.
Solubilizer and emulsifier scaffolding (claims 5 through 9)
Claim 5 allows:
- Solubilizing agent: 0.1 to 20 wt%
Claim 6 pins:
- ethanol as the solubilizing agent example.
Claim 7 allows:
- non-ionic emulsifying agent: 0.1 to 20 wt% to form a stable emulsion.
Claim 8: emulsifying agent “comprises at least one normally liquid glycol.”
Claim 9: surfactant list (non-exhaustive “selected from the group consisting of...”):
- lecithin
- sorbitan monoesters
- polysorbates
- mononylphenyl ethers of polyethyleneglycols
- polyoxyethylene monoesters
- dioctyl sodium sulfosuccinate
- sodium lauryl sulfate
- polyoxamers MW 2000 to 8000
- triethanolamine
- ureas
These dependent claims suggest the patent holder is not relying on one single excipient system. Instead, the enforced “must haves” remain the aqueous gel and the pH range with PAA, with antioxidants as the second pillar.
Lipophilic agent, preservative, chelation (claims 10 through 15)
-
Claim 10: lipophilic agent up to 10 wt%
-
Claim 11: lipophilic selection set:
- fatty alcohols C12 to C20
- fatty acid esters C12 to C20
- petrolatum
- plant oils
- mineral oils
-
Claim 12: preservative 0.05 to 2 wt%
-
Claim 13: methyl paraben, ethyl paraben, sorbitol
-
Claim 14: chelating agent up to 0.5 wt%
-
Claim 15: sodium or calcium salts of EDTA
Together, these provide a broad formulation palette under the same gel matrix. For design-arounds, the practical leverage is less about preservatives or surfactants and more about the gel former class and pH and the aqueous majority.
What does the method claim cover (claims 16 through 29)?
Independent method claim 16 mirrors composition claim 1, then adds:
- “topically applying the composition to the skin to be treated”
Dependent method claims 17 to 29 reproduce the same narrowing features as claims 2 to 15.
Method claim structure: the enforceable unit in clinical use
Because the method claim depends directly on the composition limitations, infringement analysis usually collapses into whether a product’s formulation matches the claimed aqueous PAA gel with pH 3 to 7 and the antioxidant and retinoid identity.
For market strategy, any competitor selling a “substantially similar formulation” to end users is exposed on method claims if their product is used as contemplated (topical application for tretinoin treatment of skin conditions).
Where is the likely infringement “sweet spot”?
For an accused product, coverage is most likely when the product:
- is water-based and remains ≥40 wt% water (or at least not clearly below)
- uses high molecular weight polyacrylic acid as the gelling agent
- is formulated at pH 3 to 7
- includes tretinoin in the claimed low-concentration band typical for dermatology
- contains an antioxidant that credibly retards aqueous tretinoin degradation
- presents as a slow-release gel that holds tretinoin in the matrix (even if the product marketing does not emphasize it, the formulation design likely does)
The critical point for competitive planning is that even if a competitor chooses different surfactants, solubilizers, preservatives, or lipophilic excipients, the claim continues to anchor on the gel matrix and antioxidant-retention function.
How do competitors most plausibly design around?
Within the strict claim structure, the highest-leverage design-out routes are:
1) Break the gelling agent requirement (PAA + high MW)
Claim 1 requires “a high molecular weight polyacrylic acid gelling agent.” If the formulation uses:
- a different polymer class (e.g., carbomer with different specification not meeting “polyacrylic acid” and/or “high molecular weight”),
- or polyacrylic acid but not “high molecular weight” by the patent’s implicit characterization,
- or no gel-forming polymer that “holds” tretinoin for slow release,
then the claim 1 architecture is disrupted.
2) Move pH outside 3 to 7
Claim 1 needs neutralized PAA at pH “about 3 to 7.” If a product is controlled below 3 or above 7 while still stabilizing tretinoin, it can avoid a central limitation.
3) Reduce water below the claimed threshold
At least “about 40 wt% water” is required. A product that is predominantly non-aqueous, water-limited, or uses a different continuous phase may evade the aqueous-medium limitation.
4) Remove or change the antioxidant strategy
Claim 1 needs an antioxidant effective to retard decomposition of tretinoin in the aqueous medium. A competitor that uses alternative stabilization approaches (e.g., different stabilization systems) may avoid this if the system is not “an antioxidant effective” as claimed.
5) Avoid the “retinoid is tretinoin” identity
Claim 1 is explicitly tretinoin. Substituting a different retinoid (retinal, adapalene, tazarotene) typically avoids literal infringement, though real-world exposure depends on doctrine-of-equivalents analysis and claim construction, which is a separate issue from the strict scope analysis.
What does the landscape imply for R&D product positioning?
This reissue is a classic formulation claim set: it is designed to cover a family of gel-type aqueous tretinoin compositions with antioxidants and slow-release behavior.
For a competitor, this means the “position” is primarily determined by:
- polymer and pH control strategy
- stabilization system identity
- continuous phase and water content
Switching out excipients like surfactants or preservatives can keep a product within the same therapeutic sensibility while still staying trapped inside the claims if the gel matrix remains the same.
Key claim map for fast technical diligence
| Claim element |
Where it appears |
What to test in an accused/target product dossier |
| “stable, aqueous” and ≥40 wt% water |
Claim 1 (a) |
Water content and formulation phase analysis |
| tretinoin as the retinoid |
Claim 1 (b) |
Active ingredient identity and form |
| high MW PAA gelling agent |
Claim 1 (c) |
Polymer identity and molecular weight designation/spec |
| PAA neutralization to pH 3 to 7 |
Claim 1 (c) |
Final formulation pH and neutralization chemistry |
| slow release holding function |
Claim 1 (c) |
Release profile testing and gel matrix behavior |
| antioxidant to retard decomposition |
Claim 1 (d) |
Antioxidant presence and stabilizing efficacy data |
| dependent ranges (tretinoin, PAA, antioxidant) |
Claims 2 and 17 |
Quantitative composition matching |
| antioxidant exemplars |
Claim 4 and 18 |
Whether product uses one of the listed antioxidants |
| optional solubilizer/emulsifier/surfactants |
Claims 5-9 and 19-23 |
Excipients can vary without necessarily escaping if core limitations are met |
| lipophilic agent/preservative/chelator |
Claims 10-15 and 24-29 |
Lower priority for design-around compared with polymer/pH/water |
Key Takeaways
- RE41134 claim 1 is a structured fence around an aqueous, gel-forming tretinoin formulation with high molecular weight polyacrylic acid at pH 3 to 7 plus an antioxidant to retard decomposition.
- Dependent claims expand coverage across typical excipient palettes (solubilizers, non-ionic emulsifiers, surfactants, lipophilic agents, preservatives, EDTA salts) while leaving the central “must haves” unchanged.
- The most actionable design-arounds are to break at least one of the core elements: PAA (high MW), pH 3 to 7, water content ≥40 wt%, antioxidant requirement, or tretinoin identity.
FAQs
1) Is the antioxidant requirement limited to the five listed examples?
Not in claim 1. Claim 1 requires “an amount of antioxidant effective to retard decomposition.” Claim 4 narrows to enumerated antioxidants as a dependent limitation, but claim 1 itself is broader on antioxidant selection.
2) If a product uses polyacrylic acid but at low molecular weight, does it avoid the claim?
Claim 1 specifies “high molecular weight polyacrylic acid.” If the product polymer does not meet the claim’s “high molecular weight” characterization, that is a direct non-infringement route.
3) Does changing emulsifiers or surfactants defeat infringement?
Not by itself. Claims 7 to 9 and their method equivalents list multiple excipients, while claims 1/16 keep the gel matrix (PAA + pH) and antioxidant as core limitations.
4) Is the method claim broader than the composition claim?
No. Claim 16 requires a composition that meets all claim 1 elements, then adds topical application. If the composition limitations are not met, the method claim typically fails.
5) Can a product avoid the claims by lowering water below 40 wt%?
Yes. Claim 1 requires at least about 40 wt% water in the composition’s aqueous medium. Water reduction below that threshold is a direct line-of-avoidance.
References
[1] United States Reissue Patent RE41134 (claims as provided in the prompt).
